Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.

被引：0
|
作者：
May, Michael S.
Wooster, Margaux
May, Benjamin
Shu, Catherine A.
Henick, Brian S.
Stoopler, Mark
Smith-Marrone, Stephanie
Saqi, Anjali
Mansukhani, Mahesh M.
Riely, Gregory J.
Hershman, Dawn L.
Herzberg, Benjamin
机构：
[1] Columbia Univ Med Ctr, New York, NY USA
[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA
[3] Columbia Univ, Irving Med Ctr, New York, NY USA
[4] NYP Columbia, Bronxville, NY USA
[5] Columbia Univ, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11012
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
    Shin, Hyungkyung
    Hwang, Sua
    Jeong, Jeong Hyun
    Shin, Sang Chul
    Oh, Yeonji
    Kim, Jinhyeok
    Hwang, Inah
    Kim, Eunice EunKyeong
    Choo, Hyunah
    Song, Eun Joo
    PHARMACOLOGICAL RESEARCH, 2025, 215
  • [42] SOTORASIB IS ACTIVE IN KRASG12C-MUTANT NON-SMALL CELL LUNG CANCER
    Skoulidis, F.
    Li, B. T.
    Dy, G. K.
    Price, T. J.
    Falchook, G. S.
    Wolf, J.
    CANCER DISCOVERY, 2021, 11 (08) : 1870 - 1870
  • [43] CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
    Fakih, Marwan
    Desai, Jayesh
    Kuboki, Yasutoshi
    Strickler, John H.
    Price, Timothy Jay
    Durm, Greg Andrew
    Falchook, Gerald Steven
    Denlinger, Crystal S.
    Krauss, John C.
    Shapiro, Geoffrey
    Kim, Tae Won
    Park, Keunchil
    Coveler, Andrew L.
    Munster, Pamela N.
    Li, Bob T.
    Kim, June
    Henary, Haby Adel
    Ngarmchamnanrith, Gataree
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN
    Fernandez-Barcelo, C.
    Abbas, I
    Botella, X.
    Aguilo Domingo, M.
    Cots, F.
    Siles Cuesta, C.
    Arriola, E.
    Gas Lopez, M. E.
    Lopez Gomez, C.
    Juan-Vidal, O.
    Planellas, L.
    Lloansi, A.
    Sanchez, J.
    Reguart, N.
    Sampietro-Colom, L.
    VALUE IN HEALTH, 2023, 26 (12) : S521 - S521
  • [45] Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation
    Kodama, Hiroaki
    Kenmotsu, Hirotsugu
    Kawabata, Takanori
    Notsu, Akifumi
    Yabe, Michitoshi
    Nishioka, Naoya
    Miyawaki, Eriko
    Miyawaki, Taichi
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    CANCER MEDICINE, 2021, 10 (21): : 7503 - 7513
  • [46] KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms
    Suzuki, Shinichiro
    Yonesaka, Kimio
    Teramura, Takeshi
    Takehara, Toshiyuki
    Kato, Ryoji
    Sakai, Hitomi
    Haratani, Koji
    Tanizaki, Junko
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5697 - 5707
  • [47] The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.
    Lin, Shengcheng
    Ma, Kai
    Xu, Yafei
    Liu, Xinyi
    Huang, Xiaochun
    Huang, Mengli
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] The effect of prior cancer on non-small cell lung cancer trial eligibility
    Herman, Michael
    Liu, Zhihui
    Shepherd, Frances A.
    Leighl, Natasha
    Liu, Geoffrey
    Bradbury, Penelope A.
    CANCER MEDICINE, 2021, 10 (14): : 4814 - 4822
  • [49] Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
    Janette Vardy
    Ryan Dadasovich
    Philip Beale
    Michael Boyer
    Stephen J Clarke
    BMC Cancer, 9
  • [50] Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
    Vardy, Janette
    Dadasovich, Ryan
    Beale, Philip
    Boyer, Michael
    Clarke, Stephen J.
    BMC CANCER, 2009, 9
12345